Pemphigus Vulgaris Market Report 2026

The pemphigus vulgaris market size has grown strongly in recent years. It will grow from $1.94 billion in 2025 to $2.09 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to limited awareness and delayed diagnosis, reliance on corticosteroids, insufficient access to dermatology specialists, high cost of immunosuppressive therapies, fragmented clinical data and registries.

The pemphigus vulgaris market size is expected to see strong growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to rising adoption of targeted immunotherapies, increasing use of biologics and monoclonal antibodies, expanding teledermatology and remote monitoring solutions, advancements in early detection diagnostic tools, growing patient awareness and support programs. Major trends in the forecast period include increasing use of ai for early diagnosis and prognosis prediction, growing adoption of genomics-based personalized therapies, integration of cloud and big data for patient data management, use of iot-enabled devices for remote patient monitoring, implementation of smart manufacturing in immunosuppressive drug production.

The growing prevalence of autoimmune diseases is expected to drive the growth of the pemphigus vulgaris market in the coming years. Autoimmune diseases are a group of conditions in which the immune system mistakenly attacks the body’s healthy cells, tissues, or organs. The incidence of autoimmune diseases is increasing due to factors such as genetic susceptibility, environmental triggers, and lifestyle changes. Genetic influences play a major role, as individuals with a family history of autoimmune disorders are more likely to develop these conditions because of inherited immune system vulnerabilities. As autoimmune diseases become more widespread due to these factors, a larger number of individuals are being diagnosed with conditions such as pemphigus vulgaris, increasing the demand for advanced treatment options. For instance, in January 2025, according to Mayo Clinic Health System, a US-based network of community-focused medical facilities, the global incidence and prevalence of autoimmune diseases continue to rise, with estimated annual increases of 19.1% and 12.5%, respectively. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the pemphigus vulgaris market.

Major companies operating in the pemphigus vulgaris market are emphasizing investment-based approaches to enhance treatment effectiveness and broaden available therapeutic options. Investment solutions refer to the allocation of financial resources and strategic funding toward treatment development, research activities, and market access initiatives. For example, in January 2023, the Patient Access Network Foundation (PAN Foundation), a US-based non-profit organization, introduced a financial assistance program offering up to $6,600 annually for eligible patients with pemphigus vulgaris to help cover deductibles, copayments, and coinsurance expenses. Eligibility for this assistance requires patients to be undergoing treatment for pemphigus vulgaris, have Medicare coverage for the required medications, and meet income criteria at or below 400% of the federal poverty level. In addition to financial support, the PAN Foundation provides transportation assistance and connects patients with relevant support organizations.

In December 2023, the PAN Foundation, a US-based non-profit organization, entered into a partnership with the International Pemphigus and Pemphigoid Foundation to support individuals living with pemphigus vulgaris. Through this collaboration, the PAN Foundation is able to offer financial assistance of up to $6,600 to eligible patients, along with access to educational resources and support services. The partnership aims to ease the financial burden associated with treatment and improve the overall quality of life for patients. The International Pemphigus and Pemphigoid Foundation is a US-based non-profit organization dedicated to providing support and resources for individuals affected by pemphigus vulgaris.

Major companies operating in the pemphigus vulgaris market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Amgen Inc., Sanofi S.A, Biogen Inc., Genentech, Genmab A/S, argenx SE, Daewoong Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., Artiva Biotherapeutics, Cabaletta Bio Inc., SinoMab BioScience Limited, Topas Therapeutics GmbH, Principia Biopharma Inc., Serpin Pharma LLC, Syntimmune Inc., International Pemphigus & Pemphigoid Foundation.

North America was the largest region in the pemphigus vulgaris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pemphigus vulgaris market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pemphigus vulgaris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pemphigus vulgaris market by increasing the cost of imported immunosuppressive drugs, biologics, and diagnostic equipment, affecting hospitals and specialty clinics in regions such as North America and Europe. While tariffs have temporarily raised treatment costs, they have also promoted domestic manufacturing, innovation in cost-effective therapies, and improved local supply chain resilience for critical drugs and medical devices.

The pemphigus vulgaris market research report is one of a series of new reports that provides pemphigus vulgaris market statistics, including pemphigus vulgaris industry global market size, regional shares, competitors with a pemphigus vulgaris market share, detailed pemphigus vulgaris market segments, market trends and opportunities, and any further data you may need to thrive in the pemphigus vulgaris industry. This pemphigus vulgaris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pemphigus vulgaris is a rare autoimmune disease characterized by the formation of blisters and sores on the skin and mucous membranes, including the mouth, throat, and genitals. The condition develops when the immune system incorrectly targets the proteins responsible for binding skin cells together, leading to the formation of painful blisters. These blisters are fragile and can rupture easily, leaving raw and open lesions. Pemphigus vulgaris is a chronic disorder and may become life threatening if not managed appropriately, with treatment typically involving immunosuppressive therapies to regulate the immune system’s abnormal activity.

The primary aspects of pemphigus vulgaris management include diagnosis and treatment. Diagnosis is conducted through clinical assessment, skin biopsy, and immunological testing to identify the presence of autoantibodies. The condition affects different population groups, including pediatric, adult, and geriatric patients, and products are distributed through multiple channels such as hospitals, pharmacies, retail pharmacies, and online pharmacies. It is utilized by various end users, including hospitals, specialty clinics, research institutes, and others.

The pemphigus vulgaris market consists of revenues earned by entities by providing services such as physical therapy, palliative care, patient support groups, psychological support and counseling, and immunosuppressive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pemphigus vulgaris market includes sales of skin biopsy kits and serological test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.